Market Overview

Glancy Prongay & Murray LLP Commences Investigation on Behalf of Aradigm Corporation Investors (ARDM)


Prongay & Murray LLP
("GPM") announces an investigation on
behalf of Aradigm Corporation ("Aradigm" or the "Company") (NASDAQ: ARDM)
investors concerning the Company and its officers' possible violations
of federal securities laws. To obtain information or aid in the
investigation, please visit the Aradigm investigation page on our
website at

On January 9, 2018, the U.S. Food and Drug Administration ("FDA")
released its briefing document for the January 11, 2018 meeting of the
Antimicrobial Drugs Advisory Committee to discuss the New Drug
Application for Linhaliq™ for the proposed indication of treatment of
non-cystic fibrosis bronchiectasis ("NCFB"). The FDA stated that "there
were too many uncertainties with regard to duration of treatment,
frequency of administration and endpoints to allow for reliance on a
single Phase 3 trial" of the drug, and that the FDA recommended Aradigm
conduct "two independent trials" to provide evidence supporting the
drug's "overall demonstration of efficacy and safety."

On this news, shares of Aradigm fell significantly, thereby injuring

Follow us for updates on Twitter:

If you purchased Aradigm securities, have information or would like to
learn more about these claims, or have any questions concerning this
announcement or your rights or interests with respect to these matters,
please contact Lesley
, Esquire, of GPM, 1925 Century Park East, Suite 2100, Los
Angeles, California 90067 at 310-201-9150, Toll-Free at 888-773-9224, by
email to,
or visit our website at
If you inquire by email please include your mailing address, telephone
number and number of shares purchased.

This press release may be considered Attorney Advertising in some
jurisdictions under the applicable law and ethical rules.

View Comments and Join the Discussion!